Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
Letter to FDA Requesting Extension of Comment Period for Proposed Rule on Regulation of LDTs
-
ACMG Request to FDA to Extend Comment Period for Proposed Rule on Regulation of LDTs
-
ACMG Comment to NCD on Germline Editing and Impact on People with Disabilities
-
ACMG Response to USPSTF Proposed Research Plan for Lynch Syndrome
-
Sign-on Letter Opposing Updated VALID Act & ACM Exemption
-
ACMG Letter Regarding Maryland Medicaid Policy for Carrier Screening
-
Sign-on Letter to Congressional Leadership Concerning the VALID Act
-
ACMG Comments on FDA Draft Guidance for Products Incorporating Genome Editing
-
Group Sign-on Letter Concerning the VALID Act of 2022 Discussion Draft
-
ACMG Response to Opposing Inclusion of the VALID Act in the FDASLA Act